Advanced Therapies for Blood Purification Market to Reach US$ 7.37 Billion by 2033 at 7.8% CAGR; North America Leads with 38% Share | Key Players Fresenius Medical Care, Baxter, B. Braun

The global advanced therapies for blood purification market reached US$ 3.53 billion in 2023, increased to US$ 3.78 billion in 2024, and is expected to reach US$ 7.37 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033. Market growth is driven by the rising prevalence of sepsis, chronic kidney disease, autoimmune disorders, and multi-organ failure, along with increasing adoption of advanced extracorporeal therapies in critical care settings. Technological advancements in hemoperfusion, plasmapheresis, and adsorption-based devices are improving treatment efficiency, safety, and clinical outcomes, supporting wider clinical acceptance.

North America held the largest market share due to advanced healthcare infrastructure, high adoption of innovative critical care technologies, strong reimbursement frameworks, and the presence of leading medical device manufacturers. Europe followed, supported by increasing ICU admissions, growing awareness of blood purification therapies, and favorable regulatory support for advanced medical devices. Asia-Pacific is expected to register the fastest growth, driven by rising incidence of critical illnesses, expanding hospital infrastructure, increasing healthcare expenditure, and growing adoption of advanced therapies across emerging economies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/advanced-therapies-for-blood-purification-market?sai-v
The advanced therapies for blood purification market refers to the global industry focused on innovative medical technologies and treatments designed to remove toxins, pathogens, and inflammatory substances from the blood.

Key Developments

✅ January 2026: Globally, blood purification technology providers accelerated integration of AI-driven analytics and real-time monitoring into advanced hemoperfusion and continuous renal replacement therapy systems to optimize cytokine removal and fluid management in critically ill patients.

✅ December 2025: In the United States, leading blood and cell therapy companies entered strategic collaborations to advance next-generation therapeutic apheresis solutions targeting sepsis and systemic inflammatory conditions through selective toxin and biomarker removal.

✅ December 2025: In North America, expansion of pathogen reduction and blood safety technologies supported wider adoption of advanced purification systems in transfusion medicine and critical care settings.

✅ September 2025: Globally, medical device manufacturers launched portable and compact blood purification and dialysis platforms designed to support outpatient, emergency, and home-care applications.

✅ August 2025: In Europe, blood purification equipment developers announced upgrades to filtration membranes and adsorption cartridges aimed at improving removal efficiency of inflammatory mediators and middle-molecular-weight toxins.

✅ July 2025: In Asia-Pacific, manufacturers expanded production capacity and regional supply chains for advanced blood purification devices to address rising demand from intensive care units and dialysis centers.

Mergers & Acquisitions

✅ January 2026: In the global medical device sector, a large cardiovascular and interventional technologies company announced the acquisition of a specialist critical care device business, strengthening its portfolio with solutions applicable to extracorporeal blood management and purification therapies.

✅ December 2025: In Europe, a medical technology group completed the acquisition of a filtration and adsorption technology company to enhance its advanced blood purification and critical care product offerings.

✅ October 2025: In North America, a healthcare equipment manufacturer acquired a niche blood purification startup focused on innovative adsorption-based therapies for sepsis and inflammatory diseases.

Key Players
Fresenius Medical Care AG | Baxter | B. Braun SE | Nikkiso Belgium BV | Asahi Kasei Medical Co., Ltd. | Medtronic | Aethlon Medical, Inc. | Others

Key Highlights
Fresenius Medical Care AG holds 34.6% share, driven by its global leadership in dialysis products and services, vertically integrated business model, and extensive clinical network.

Baxter holds 21.8% share, supported by its strong portfolio of renal care solutions, continuous product innovation, and broad adoption across hospitals and dialysis centers.

B. Braun SE holds 15.2% share, leveraging its expertise in medical devices and extracorporeal therapies, strong presence in Europe, and focus on quality and safety.

Nikkiso Belgium BV holds 10.7% share, driven by advanced dialysis systems, technological innovation, and growing penetration in hospital-based renal care.

Asahi Kasei Medical Co., Ltd. holds 9.1% share, supported by its high-performance dialyzers, membrane technologies, and strong footprint in Asia-Pacific markets.

Medtronic holds 6.3% share, leveraging its broad medical technology expertise, integrated renal care solutions, and global distribution capabilities.

Aethlon Medical, Inc. holds 1.5% share, focused on niche blood purification technologies and innovative extracorporeal treatment platforms.

Others account for 0.8% share, comprising regional manufacturers and emerging players offering specialized dialysis and blood purification solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=advanced-therapies-for-blood-purification-market?sai-v

Market Drivers
- Rising prevalence of chronic kidney disease, sepsis, autoimmune disorders, and critical care conditions requiring advanced blood purification solutions.

- Increasing incidence of multi-organ failure and cytokine storm syndromes driving demand for extracorporeal blood purification therapies.

- Growing adoption of advanced hemofiltration, hemoperfusion, and adsorption technologies in intensive care units.

- Technological advancements improving membrane selectivity, biocompatibility, and treatment efficiency.

Expanding awareness among clinicians about early intervention benefits in critical and life-threatening conditions.

Industry Developments
- Development of next-generation adsorption cartridges and membranes targeting endotoxins, cytokines, and inflammatory mediators.

- Increasing integration of blood purification therapies with continuous renal replacement therapy (CRRT) platforms.

- Strategic collaborations between medical device manufacturers, hospitals, and research institutions to validate clinical outcomes.

- Rising investments in portable and bedside blood purification systems for ICU and emergency care settings.

- Expansion of clinical trials evaluating blood purification efficacy in sepsis, COVID-related complications, and autoimmune diseases.

Regional Insights
North America - 38% share: "Driven by advanced critical care infrastructure, high ICU admission rates, strong adoption of innovative extracorporeal therapies, and favorable reimbursement policies."

Europe - 30% share: "Supported by well-established dialysis networks, strong clinical research activity, and growing use of blood purification in sepsis management."

Asia Pacific - 22% share: "Fueled by rising chronic disease burden, expanding ICU capacity, increasing healthcare investments, and adoption of advanced medical technologies."

Latin America - 6% share: "Driven by gradual improvements in critical care infrastructure and increasing awareness of advanced blood purification therapies."

Middle East & Africa - 4% share: "Supported by expanding hospital infrastructure, rising investments in critical care services, and growing focus on advanced therapeutic technologies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/advanced-therapies-for-blood-purification-market?sai-v

Key Segments

By Therapy Type
Hemodialysis represents the largest segment, driven by its widespread use in managing chronic and end-stage kidney disease and its strong presence in hospital and dialysis center settings. Hemofiltration is gaining traction, particularly in critical care environments, due to its effectiveness in fluid management and removal of middle-molecular-weight toxins. Plasmapheresis holds a significant share, supported by its growing application in autoimmune and neurological disorders requiring rapid removal of pathogenic substances. Hemoperfusion is witnessing steady adoption for the treatment of toxicological emergencies and drug overdoses, owing to its ability to adsorb specific toxins directly from the blood. Continuous renal replacement therapy (CRRT) is a key segment in intensive care units, driven by rising incidence of acute kidney injury and hemodynamically unstable patients. Extracorporeal membrane oxygenation (ECMO) represents a specialized but critical segment, increasingly used in severe cardiac and respiratory failure cases. Other therapies include hybrid and emerging extracorporeal techniques, contributing modestly to overall market growth.

By Application
End-stage kidney disease accounts for a major application segment due to the long-term dependence on dialysis-based therapies. Acute kidney injury represents a significant share, driven by increasing ICU admissions and rising prevalence of critical illnesses. Multi-organ failure is an expanding application area, supported by growing use of advanced extracorporeal support systems in critical care settings. Sepsis and septic shock are witnessing rising adoption of blood purification therapies due to increasing awareness of cytokine removal and immune modulation benefits. Toxicological emergencies form a smaller but vital segment, driven by demand for rapid detoxification in poisoning and overdose cases. Autoimmune disorders are gaining attention as an application area, particularly with increased use of plasmapheresis for immune-mediated conditions. Other applications include metabolic disorders and rare indications requiring extracorporeal blood purification.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.